Jerod Nagel

2.7k total citations
57 papers, 1.6k citations indexed

About

Jerod Nagel is a scholar working on Infectious Diseases, Applied Microbiology and Biotechnology and Epidemiology. According to data from OpenAlex, Jerod Nagel has authored 57 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 24 papers in Applied Microbiology and Biotechnology and 19 papers in Epidemiology. Recurrent topics in Jerod Nagel's work include Antibiotic Use and Resistance (24 papers), Bacterial Identification and Susceptibility Testing (19 papers) and Neutropenia and Cancer Infections (9 papers). Jerod Nagel is often cited by papers focused on Antibiotic Use and Resistance (24 papers), Bacterial Identification and Susceptibility Testing (19 papers) and Neutropenia and Cancer Infections (9 papers). Jerod Nagel collaborates with scholars based in United States and Netherlands. Jerod Nagel's co-authors include Tejal Gandhi, Laraine Washer, Duane W. Newton, Angela Huang, Anjly Kunapuli, Curtis D. Collins, Twisha S Patel, Bernard L. Marini, William A. Prescott and Keith S. Kaye and has published in prestigious journals such as Annals of Internal Medicine, Clinical Infectious Diseases and Journal of Clinical Microbiology.

In The Last Decade

Jerod Nagel

55 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jerod Nagel United States 20 706 699 542 536 254 57 1.6k
Tristan T. Timbrook United States 18 716 1.0× 602 0.9× 420 0.8× 502 0.9× 220 0.9× 57 1.5k
Karri A. Bauer United States 24 572 0.8× 686 1.0× 833 1.5× 586 1.1× 442 1.7× 54 1.9k
Aisling R. Caffrey United States 21 610 0.9× 508 0.7× 379 0.7× 530 1.0× 326 1.3× 84 1.6k
Michelle T. Hecker United States 14 528 0.7× 334 0.5× 431 0.8× 720 1.3× 143 0.6× 37 1.7k
David T. Bearden United States 20 958 1.4× 335 0.5× 388 0.7× 1.1k 2.0× 312 1.2× 39 2.0k
Edina Avdic United States 18 667 0.9× 430 0.6× 753 1.4× 353 0.7× 417 1.6× 39 1.7k
Kimberly C. Claeys United States 24 527 0.7× 596 0.9× 378 0.7× 535 1.0× 429 1.7× 103 1.4k
Michael Postelnick United States 26 486 0.7× 498 0.7× 517 1.0× 696 1.3× 754 3.0× 88 2.3k
John J. Engemann United States 18 1.0k 1.5× 672 1.0× 280 0.5× 1.4k 2.5× 214 0.8× 23 2.5k
Marina de Cueto Spain 21 864 1.2× 481 0.7× 288 0.5× 278 0.5× 222 0.9× 51 1.7k

Countries citing papers authored by Jerod Nagel

Since Specialization
Citations

This map shows the geographic impact of Jerod Nagel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerod Nagel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerod Nagel more than expected).

Fields of papers citing papers by Jerod Nagel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerod Nagel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerod Nagel. The network helps show where Jerod Nagel may publish in the future.

Co-authorship network of co-authors of Jerod Nagel

This figure shows the co-authorship network connecting the top 25 collaborators of Jerod Nagel. A scholar is included among the top collaborators of Jerod Nagel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerod Nagel. Jerod Nagel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lamb, Gabriella S, Tanvi Sharma, Jerod Nagel, et al.. (2023). Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study. Journal of the Pediatric Infectious Diseases Society. 12(3). 152–155. 1 indexed citations
2.
3.
Arora, Nonie S., Rebecca Hanson, Jerod Nagel, et al.. (2023). A novel 2-step process for the management of inpatient beta-lactam allergy labels. Annals of Allergy Asthma & Immunology. 132(4). 525–531.e1. 1 indexed citations
4.
Tribble, Alison C., et al.. (2023). 962. Impact of Care Bundle Element Compliance on Clinical Outcomes for Pediatric Patients with Staphylococcus aureus Bacteremia. Open Forum Infectious Diseases. 10(Supplement_2).
5.
Kaye, Keith S., et al.. (2022). Improving antibiotic use for sinusitis and upper respiratory tract infections: A virtual-visit antibiotic stewardship initiative. Infection Control and Hospital Epidemiology. 43(12). 1890–1893. 8 indexed citations
6.
Pogue, Jason M., Adam S. Lauring, Tejal Gandhi, et al.. (2021). Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants. Open Forum Infectious Diseases. 8(7). ofab268–ofab268. 1 indexed citations
7.
Zhou, Shiwei, Jerod Nagel, Keith S. Kaye, et al.. (2021). Antimicrobial Stewardship and the Infection Control Practitioner. Infectious Disease Clinics of North America. 35(3). 771–787. 7 indexed citations
8.
Nagel, Jerod, et al.. (2020). Stewardship-Hospitalist Collaboration. Infectious Disease Clinics of North America. 34(1). 83–96. 5 indexed citations
9.
Mills, John, Christopher Zimmerman, Tejal Gandhi, et al.. (2020). Incorporating preauthorization into antimicrobial stewardship pharmacist workflow reduces Clostridioides difficile and gastrointestinal panel testing. Infection Control and Hospital Epidemiology. 41(10). 1136–1141. 9 indexed citations
10.
Vaughn, Valerie M., Scott A. Flanders, Ashley Snyder, et al.. (2019). Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia. Annals of Internal Medicine. 1 indexed citations
11.
Tang, Laura, Bernard L. Marini, Lydia L. Benitez, et al.. (2017). Risk factors for subtherapeutic levels of posaconazole tablet. Journal of Antimicrobial Chemotherapy. 72(10). 2902–2905. 38 indexed citations
12.
Perissinotti, Anthony J., et al.. (2017). Risk factors and impact of Clostridium difficile recurrence on haematology patients. Journal of Antimicrobial Chemotherapy. 72(5). 1488–1495. 32 indexed citations
13.
Nagel, Jerod, Twisha S Patel, Tejal Gandhi, et al.. (2016). Effect of an antimicrobial stewardship intervention on outcomes for patients with Clostridium difficile infection. American Journal of Infection Control. 44(12). 1539–1543. 12 indexed citations
14.
Marini, Bernard L., et al.. (2016). Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia. Supportive Care in Cancer. 25(2). 541–547. 7 indexed citations
15.
Alaniz, Cesar, et al.. (2015). Recurrent Clostridium difficile infection in intensive care unit patients. American Journal of Infection Control. 44(1). 36–40. 10 indexed citations
16.
Marini, Bernard L., et al.. (2015). Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia. Supportive Care in Cancer. 23(8). 2287–2295. 13 indexed citations
17.
Nagel, Jerod, James G. Stevenson, Edward H. Eiland, & Keith S. Kaye. (2014). Demonstrating the Value of Antimicrobial Stewardship Programs to Hospital Administrators. Clinical Infectious Diseases. 59(suppl_3). S146–S153. 37 indexed citations
18.
19.
Smith, Jennifer A., et al.. (2012). Evaluation of the effect of obesity on voriconazole serum concentrations. Journal of Antimicrobial Chemotherapy. 67(12). 2957–2962. 42 indexed citations
20.
Gandhi, Tejal, Daryl D. DePestel, Curtis D. Collins, Jerod Nagel, & Laraine Washer. (2010). Managing antimicrobial resistance in intensive care units. Critical Care Medicine. 38(8 Suppl). S315–S323. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tristan T. Timbrook Breakdown of academic impact, for papers by Karri A. Bauer Breakdown of academic impact, for papers by Aisling R. Caffrey Breakdown of academic impact, for papers by Michelle T. Hecker Breakdown of academic impact, for papers by David T. Bearden Breakdown of academic impact, for papers by Edina Avdic Breakdown of academic impact, for papers by Kimberly C. Claeys Breakdown of academic impact, for papers by Michael Postelnick Breakdown of academic impact, for papers by John J. Engemann Breakdown of academic impact, for papers by Marina de Cueto
Rankless by CCL
2026